KRAS and non-small cell lung carcinoma: Therefore, uncovering common and distinct biological processes and phosphorylation events among oncogenic EGFR‐mutant, KRAS mutant, and EML4–ALK‐rearranged LUADs through proteomics and phosphoproteomics analyses could provide significant insights for further studies developing diagnostic approaches or therapeutic strategies for NSCLC.